NCT02332109View on ClinicalTrials.gov

ODM 5 in the Treatment of Corneal Edematous Fuchs' Endothelial Dystrophy

CompletedOBSERVATIONAL
Enrollment

29

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

May 31, 2016

Study Completion Date

May 31, 2016

Conditions
Fuchs' Endothelial DystrophyCorneal Edema
Interventions
DEVICE

ODM 5

ODM 5 is a CE-certified, preservative-free, hyperosmolar ophthalmological solution containing 5% sodium chloride and 0.15% sodium hyaluronate recommended for the reduction of corneal edema. The patient will use ODM 5 on a daily basis in accordance with the instructions for use and as recommended by the investigator over a period of 8 weeks.

Trial Locations (4)

39120

Universitätsklinikum Magdeburg A.ö.R., Universitätsaugenklinik, Magdeburg

40225

Universitätsklinikum Düsseldorf, Augenklinik, Düsseldorf

69121

Praxis Dr. Thomas Kaercher, Heidelberg

80336

Augenklinik der Ludwig-Maximilians-Universität (LMU), Klinikum der Universität München, München

All Listed Sponsors
lead

TRB Chemedica AG

INDUSTRY

NCT02332109 - ODM 5 in the Treatment of Corneal Edematous Fuchs' Endothelial Dystrophy | Biotech Hunter | Biotech Hunter